Novartis says Signifor LAR drug helps control acromegaly disease

ZURICH Mon May 5, 2014 1:47am EDT

Pigeons sit on a roof in front of the logo of Swiss drugmaker Novartis at the company's plant in Basel January 28, 2009. REUTERS/Arnd Wiegmann

Pigeons sit on a roof in front of the logo of Swiss drugmaker Novartis at the company's plant in Basel January 28, 2009.

Credit: Reuters/Arnd Wiegmann

Related Topics

ZURICH (Reuters) - Swiss drugmaker Novartis said on Monday a final-stage trial of its Signifor LAR therapy allowed for greater disease control in patients with the endocrine disorder acromegaly than existing therapies.

Acromegaly is caused by a benign tumor in the pituitary gland that secretes excess growth hormone, and can lead to the enlargement of body parts, including the hands, feet and facial features.

Worldwide regulatory filings for pasireotide LAR in acromegaly are currently underway based on these results, Novartis said.

(Reporting by Alice Baghdjian)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

Pictures